MetaCap

Monopar Therapeutics Inc. (MNPR)

NASDAQ: MNPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

69.00-1.29 (-1.84%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MNPR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$467.60M
EPS (TTM)
-$2.44
52-week range
50.07 – 124.82
Day range
67.36 – 69.86
Volume / Avg
132.61K / 151.83K
Beta
—

52-week range

$50.07$124.82

MNPR stock today

Monopar Therapeutics (MNPR) closed at $69.00 on Nov 20, down 1.84% (-$1.29), versus the S&P 500's 3.70% decline. Shares are 44.7% below their 52-week high of $124.82, set on Aug 6, 2026 and 37.8% above the 52-week low of $50.07, in the middle of the past year's range. MNPR is up 5.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 24.6%.

Monopar Therapeutics has posted a net loss over the last twelve months (EPS of -$2.44), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Monopar Therapeutics

Company profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.
Headquarters
Wilmette, IL
Employees
22
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Monopar Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Monopar Therapeutics reported a net loss of $13.7 million, compared with a loss of $15.6 million a year earlier.

Monopar Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0———
Growth—————
Net income$-13.72M$-15.59M$-8.40M$-10.52M$-9.10M
EPS (diluted)————$-0.73

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$130.17+88.65%

  • Strong buy 4
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $119.00High $145.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.72 vs $-0.86
Surprise
+16.28%

MNPR news

All MNPR news

Monopar Therapeutics peers

Health Care sector
MNPR peer companies
CompanyPrice% ChgMarket capCompare
EVOEvotec SE ADR1.32-8.97%$469.11Mvs MNPR
RZLTRezolute Inc.3.92-6.67%$465.58Mvs MNPR
HELPHelus Pharma Inc.6.11-9.88%$487.68Mvs MNPR
BLSMBlossomHill Therapeutics Inc.14.51+0.69%$461.20Mvs MNPR
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs MNPR
NGNENeurogene Inc.22.15-3.40%$458.53Mvs MNPR
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs MNPR
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs MNPR

Indexes, lists and sector

Monopar Therapeutics stock FAQ

What is Monopar Therapeutics's stock price today?

MNPR last traded at $69.00 as of Nov 20, 4:00 PM EST, down 1.84% on the day. Prices are delayed at least 15 minutes.

Does Monopar Therapeutics pay a dividend?

No. Monopar Therapeutics does not currently pay a regular cash dividend.

Who is Monopar Therapeutics's CEO?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. is the chief executive officer of Monopar Therapeutics Inc., which has about 22 employees.

Has MNPR ever split its stock?

Yes. The most recent MNPR stock split was a 1-for-5 split on Aug 13, 2024.

What is the MNPR 52-week high?

The 52-week high for MNPR is $124.82 and the 52-week low is $50.07. The stock is currently 44.7% below its high.

Compare MNPR